Connect with us

Technology

OPENLANE, Inc. Reports 2024 Financial Results

Published

on

CARMEL, Ind., Feb. 19, 2025 /PRNewswire/ — OPENLANE, Inc. (NYSE: KAR), today reported its fourth quarter and annual financial results for the period ended December 31, 2024.

“OPENLANE delivered positive fourth quarter and full-year 2024 results, driven by another strong quarter in our marketplace business,” said Peter Kelly, CEO. “The Marketplace grew year-over-year volume for the seventh straight quarter, including 15% growth in dealer volumes, and grew Adjusted EBITDA by an impressive 30%. Our customers are clearly responding to our unique offerings and our differentiated value proposition that delivers ease, speed and improved outcomes. We remain focused on our strategy – delivering the best marketplace, technology and customer experience, and are well positioned for continued growth.”

“OPENLANE’s consistent growth and financial performance clearly demonstrate the strong scalability characteristics of our asset-light, digital model,” said Brad Lakhia, Chief Financial Officer. “Our culture of innovation, growth and financial discipline increased revenue, reduced cost and delivered $293 million in Adjusted EBITDA. We will continue to lean into our marketplace go-to-market investments to drive growth while leveraging our leading, high-performing finance business.”

Fourth Quarter Highlights

Marketplace total volume YoY growth of 9%, with dealer YoY growth of 15%Consolidated revenue of $455 million, representing 12% YoY growth, driven by 18% YoY Marketplace growthConsolidated income from continuing operations of $52 million, with Marketplace contributing $26 millionConsolidated Adjusted EBITDA of $73 million, representing 18% YoY growthMarketplace Adjusted EBITDA of $31 million, representing 30% YoY growth

Full Year Highlights

Marketplace total volume YoY growth of 9%Consolidated revenue of $1,789 million, representing 5% YoY growth, driven by 8% YoY Marketplace growthConsolidated income from continuing operations of $110 million, with Marketplace contributing $2 millionConsolidated Adjusted EBITDA of $293 million, representing 8% YoY growthCash flow from operating activities of $293 millionMarketplace Adjusted EBITDA of $135 million, representing 24% YoY growthGross Merchandise Value (GMV) of approximately $27 billion, representing 12% YoY growth

2025 Guidance

Annual

Guidance

Income from continuing operations (in millions)

$100 – $114

Adjusted EBITDA (in millions)

$290 – $310

Income from continuing operations per share – diluted *

$0.38 – $0.48

Operating adjusted net income from continuing operations per share – diluted

$0.90 – $1.00

*

The company uses the two-class method of calculating income from continuing operations per diluted share.

Under the two-class method, income from continuing operations is adjusted for dividends and undistributed

earnings (losses) to the holders of the Series A Preferred Stock, and the weighted average diluted shares do

not assume conversion of the preferred shares to common shares.

The December 2024 divestiture of the company’s automotive key business is reflected in the 2025 guidance.

Earnings guidance does not contemplate future items such as business development activities, strategic developments (such as restructurings, spin-offs or dispositions of assets or investments), contingent purchase price adjustments, significant expenses related to litigation, tax adjustments, adverse changes in the value of foreign currencies relative to the U.S. dollar, changes in applicable laws and regulations (including significant accounting and tax matters) and intangible impairments. The timing and amounts of these items are highly variable, difficult to predict, and of a potential size that could have a substantial impact on the company’s reported results for any given period. Prospective quantification of these items is generally not practicable. Operating adjusted net income from continuing operations per share excludes amortization expense associated with acquired intangible assets, as well as one-time charges, net of taxes. See reconciliations of the company’s guidance included below.

Earnings Conference Call Information
OPENLANE will be hosting an earnings conference call and webcast on Wednesday, February 19, 2025 at 5:00 p.m. ET. The call will be hosted by OPENLANE Chief Executive Officer Peter Kelly and Chief Financial Officer Brad Lakhia. The conference call may be accessed by calling 1-833-634-2155 and asking to join the OPENLANE call. A live webcast will be available at the investor relations section of corporate.openlane.com. Supplemental financial information for OPENLANE’s fourth quarter 2024 results is available at the investor relations section of corporate.openlane.com.

The archive of the webcast will be available following the call at the investor relations section of corporate.openlane.com for a limited time.

About OPENLANE
OPENLANE, Inc. (NYSE: KAR), provides sellers and buyers across the global wholesale used vehicle industry with innovative, technology-driven remarketing solutions. OPENLANE’s unique end-to-end platform supports whole car, financing, logistics and other ancillary and related services. Our integrated marketplaces reduce risk, improve transparency and streamline transactions for customers around the globe. Headquartered in Carmel, Indiana, OPENLANE has employees across the United States, Canada, Europe, Uruguay and the Philippines. For more information and the latest OPENLANE news, visit corporate.openlane.com.

Forward-Looking Statements
Certain statements contained in this release include, and the company may make related oral, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and which are subject to certain risks, trends and uncertainties. In particular, statements made that are not historical facts (including but not limited to statements regarding our growth opportunities and strategies, industry outlook, competitive position, business and investment plans and initiatives, and 2025 financial guidance) may be forward-looking statements. Words such as “should,” “may,” “will,” “would,” “anticipate,” “expect,” “project,” “intend,” “contemplate,” “plan,” “believe,” “seek,” “estimate,” “assume,” “can,” “could,” “continue,” “of the opinion,” “confident,” “is set,” “is on track,” “outlook,” “target,” “position,” “predict,” “initiative,” “goal,” “opportunity” and similar expressions identify forward-looking statements. Such statements are based on management’s current assumptions, expectations and/or beliefs, are not guarantees of future performance and are subject to substantial risks, uncertainties and changes that could cause actual results to differ materially from the results projected, expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled “Risk Factors” in the company’s annual and quarterly periodic reports, and in the company’s other filings and reports filed with the Securities and Exchange Commission. The forward-looking statements are made as of the date of this release. The company undertakes no obligation to update any forward-looking statements.

 

OPENLANE, Inc.
Condensed Consolidated Statements of Income 
(In millions) (Unaudited)

Three Months Ended
December 31,

Year Ended
December 31,

2024

2023

2024

2023

Operating revenues

Auction fees

$      112.0

$        90.0

$      443.8

$      395.3

Service revenue

141.2

144.5

586.6

619.7

Purchased vehicle sales

95.6

60.2

327.0

236.7

Finance revenue

106.2

111.4

431.1

444.0

Total operating revenues

455.0

406.1

1,788.5

1,695.7

Operating expenses

Cost of services (exclusive of depreciation and amortization)

244.5

204.8

956.3

867.6

Finance interest expense

28.3

34.0

123.5

130.6

Provision for credit losses

12.1

17.2

54.3

59.2

Selling, general and administrative

99.7

101.4

408.6

421.8

Depreciation and amortization

23.0

25.3

95.2

101.5

Gain on sale of business

(31.6)

—

(31.6)

—

Goodwill and other intangibles impairment

—

—

—

250.8

Total operating expenses

376.0

382.7

1,606.3

1,831.5

Operating profit (loss)

79.0

23.4

182.2

(135.8)

Interest expense

4.6

5.3

21.8

25.2

Other expense (income), net

5.4

(3.1)

2.5

(15.6)

Loss on extinguishment of debt

—

—

—

1.1

Income (loss) from continuing operations before income taxes

69.0

21.2

157.9

(146.5)

Income taxes

16.7

7.6

48.0

8.3

Income (loss) from continuing operations

52.3

13.6

109.9

(154.8)

Income from discontinued operations, net of income taxes

—

0.7

—

0.7

Net income (loss)

$        52.3

$        14.3

$      109.9

$    (154.1)

Net income (loss) per share – basic

Income (loss) from continuing operations

$        0.29

$        0.02

$        0.46

$      (1.83)

Income from discontinued operations

—

—

—

0.01

Net income (loss) per share – basic

$        0.29

$        0.02

$        0.46

$      (1.82)

Net income (loss) per share – diluted

Income (loss) from continuing operations

$        0.29

$        0.02

$        0.45

$      (1.83)

Income from discontinued operations

—

—

—

0.01

Net income (loss) per share – diluted

$        0.29

$        0.02

$        0.45

$      (1.82)

 

OPENLANE, Inc.
Condensed Consolidated Balance Sheets
(In millions) (Unaudited)

December 31, 
2024

December 31, 
2023

Cash and cash equivalents

$                143.0

$                 93.5

Restricted cash

40.7

65.4

Trade receivables, net of allowances

248.2

291.8

Finance receivables, net of allowances

2,322.7

2,282.0

Other current assets

96.9

109.2

Total current assets

2,851.5

2,841.9

Goodwill

1,222.9

1,271.2

Customer relationships, net of accumulated amortization

117.7

136.1

Operating lease right-of-use assets

67.1

75.9

Property and equipment, net of accumulated depreciation

149.3

169.8

Intangible and other assets

213.8

231.4

Total assets

$             4,622.3

$             4,726.3

Current liabilities, excluding obligations collateralized by

     finance receivables and current maturities of debt

$                682.7

$                692.3

Obligations collateralized by finance receivables

1,660.3

1,631.9

Current maturities of debt

222.5

154.6

Total current liabilities

2,565.5

2,478.8

Long-term debt

—

202.4

Operating lease liabilities

60.4

70.4

Other non-current liabilities

41.2

35.2

Temporary equity

612.5

612.5

Stockholders’ equity

1,342.7

1,327.0

Total liabilities, temporary equity and stockholders’ equity

$             4,622.3

$             4,726.3

 

OPENLANE, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions) (Unaudited)

Year Ended
December 31,

2024

2023

Operating activities

Net income (loss)

$         109.9

$       (154.1)

Net income from discontinued operations

—

(0.7)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Depreciation and amortization

95.2

101.5

Provision for credit losses

54.3

59.2

Deferred income taxes

1.7

(29.8)

Amortization of debt issuance costs

9.1

8.7

Stock-based compensation

14.7

16.5

Contingent consideration adjustment

—

1.3

Investment and note receivable impairment

—

10.3

Gain on sale of property

(31.6)

—

Goodwill and other intangibles impairment

—

250.8

Loss on extinguishment of debt

—

1.1

Other non-cash, net

(0.3)

1.0

Changes in operating assets and liabilities, net of acquisitions:

Trade receivables and other assets

44.4

(66.0)

Accounts payable and accrued expenses

(4.6)

39.8

Payments of contingent consideration in excess of acquisition-date fair value

—

(2.6)

Net cash provided by operating activities – continuing operations

292.8

237.0

Net cash used by operating activities – discontinued operations

(1.4)

(1.6)

Investing activities

Net (increase) decrease in finance receivables held for investment

(96.7)

64.8

Acquisition of businesses (net of cash acquired)

—

(103.0)

Purchases of property, equipment and computer software

(53.0)

(52.0)

Investments in securities

(2.8)

(1.3)

Proceeds from sale of investments

0.9

—

Proceeds from note receivable

—

0.7

Proceeds from the sale of business

79.8

—

Proceeds from the sale of property and equipment

0.9

0.3

Net cash used by investing activities – continuing operations

(70.9)

(90.5)

Net cash provided by investing activities – discontinued operations

—

7.0

Financing activities

Net increase (decrease) in book overdrafts

0.8

(2.3)

Net (repayments of) borrowings on lines of credit

(131.7)

5.9

Net increase (decrease) in obligations collateralized by finance receivables

49.5

(55.9)

Payments for debt issuance costs/amendments

(15.1)

(6.7)

Payment for early extinguishment of debt

—

(140.1)

Payments on finance leases

(0.9)

(1.9)

Payments of contingent consideration and deferred acquisition costs

—

(12.4)

Issuance of common stock under stock plans

1.4

2.7

Tax withholding payments for vested RSUs

(3.5)

(2.6)

Repurchase and retirement of common stock

(30.0)

(22.2)

Dividends paid on Series A Preferred Stock

(44.4)

(44.4)

Net cash used by financing activities – continuing operations

(173.9)

(279.9)

Net cash provided by financing activities – discontinued operations

—

—

Net change in cash balances of discontinued operations

—

—

Effect of exchange rate changes on cash

(21.8)

9.2

Net increase (decrease) in cash, cash equivalents and restricted cash

24.8

(118.8)

Cash, cash equivalents and restricted cash at beginning of period

158.9

277.7

Cash, cash equivalents and restricted cash at end of period

$         183.7

$         158.9

Cash paid for interest

$         140.7

$         145.2

Cash paid for taxes, net of refunds – continuing operations

$           36.6

$           35.8

Cash paid for taxes, net of refunds – discontinued operations

$           (1.8)

$             1.5

OPENLANE, Inc.
Reconciliation of Non-GAAP Financial Measures

EBITDA, Adjusted EBITDA, operating adjusted net income (loss) and operating adjusted net income (loss) per share as presented herein are supplemental measures of our performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). They are not measurements of our financial performance under GAAP and should not be considered as substitutes for net income (loss), operating profit (loss) or any other performance measures derived in accordance with GAAP. Management believes that these measures provide investors additional meaningful methods to evaluate certain aspects of the company’s results period over period and for the other reasons set forth below.

EBITDA is defined as net income (loss), plus interest expense net of interest income, income tax provision (benefit), depreciation and amortization. Adjusted EBITDA is EBITDA adjusted for the items of income and expense and expected incremental revenue and cost savings as described in our senior secured credit agreement covenant calculations. Management believes that the inclusion of supplementary adjustments to EBITDA applied in presenting Adjusted EBITDA is appropriate to provide additional information to investors about one of the principal measures of performance used by our creditors. In addition, management uses EBITDA and Adjusted EBITDA to evaluate our performance.

Depreciation expense for property and equipment and amortization expense of capitalized internally developed software costs relate to ongoing capital expenditures; however, amortization expense associated with acquired intangible assets, such as customer relationships, software, tradenames and noncompete agreements are not representative of ongoing capital expenditures, but have a continuing effect on our reported results. Non-GAAP financial measures of operating adjusted net income (loss) and operating adjusted net income (loss) per share, in the opinion of the company, provide comparability of the company’s performance to other companies that may not have incurred these types of non-cash expenses or that report a similar measure. In addition, operating adjusted net income (loss) and operating adjusted net income (loss) per share may include adjustments for certain other charges.

EBITDA, Adjusted EBITDA, operating adjusted net income (loss) and operating adjusted net income (loss) per share have limitations as analytical tools, and should not be considered in isolation or as a substitute for analysis of the results as reported under GAAP. These measures may not be comparable to similarly titled measures reported by other companies.

The following tables reconcile EBITDA and Adjusted EBITDA to income (loss) from continuing operations for the periods presented:

Three Months Ended

December 31,

Year Ended

December 31,

(In millions), (Unaudited)

2024

2023

2024

2023

Income (loss) from continuing operations

$      52.3

$      13.6

$     109.9

$   (154.8)

Add back:

Income taxes

16.7

7.6

48.0

8.3

Finance interest expense

28.3

34.0

123.5

130.6

Interest expense, net of interest income

4.1

4.9

20.2

21.7

Depreciation and amortization

23.0

25.3

95.2

101.5

EBITDA

124.4

85.4

396.8

107.3

Non-cash stock-based compensation

1.1

3.6

15.9

17.4

Loss on extinguishment of debt

—

—

—

1.1

Acquisition related costs

0.1

2.0

0.6

3.1

Securitization interest

(25.7)

(31.4)

(112.7)

(120.4)

Gain on sale of business

(31.6)

—

(31.6)

—

Severance

2.4

2.1

11.6

5.5

Foreign currency (gains)/losses

6.5

(2.1)

5.8

(2.9)

Goodwill and other intangibles impairment

—

—

—

250.8

Contingent consideration adjustment

—

—

—

1.3

(Gain) loss on investments

(0.4)

(0.4)

(0.4)

—

Professional fees related to business improvement efforts

—

2.1

1.5

6.6

Impact for newly enacted Canadian DST related to prior years

(4.6)

—

5.4

—

Other

0.5

0.5

0.5

2.2

  Total addbacks/(deductions)

(51.7)

(23.6)

(103.4)

164.7

Adjusted EBITDA

$      72.7

$      61.8

$     293.4

$     272.0

 

Three Months Ended December 31, 2024

(Dollars in millions), (Unaudited)

Marketplace

Finance

Consolidated

Income from continuing operations

$           25.9

$           26.4

$           52.3

Add back:

Income taxes

7.3

9.4

16.7

Finance interest expense

—

28.3

28.3

Interest expense, net of interest income

4.1

—

4.1

Depreciation and amortization

20.0

3.0

23.0

EBITDA

57.3

67.1

124.4

Non-cash stock-based compensation

0.9

0.2

1.1

Acquisition related costs

0.1

—

0.1

Securitization interest

—

(25.7)

(25.7)

Gain on sale of business

(31.6)

—

(31.6)

Severance

2.3

0.1

2.4

Foreign currency (gains)/losses

6.4

0.1

6.5

(Gain)/loss on investments

(0.4)

—

(0.4)

Impact for newly enacted Canadian DST related to prior years

(4.6)

—

(4.6)

Other

0.5

—

0.5

  Total addbacks/(deductions)

(26.4)

(25.3)

(51.7)

Adjusted EBITDA

$           30.9

$           41.8

$           72.7

 

Year Ended December 31, 2024

(Dollars in millions), (Unaudited)

Marketplace

Finance

Consolidated

Income from continuing operations

$             1.7

$          108.2

$          109.9

Add back:

Income taxes

11.3

36.7

48.0

Finance interest expense

—

123.5

123.5

Interest expense, net of interest income

20.2

—

20.2

Depreciation and amortization

83.3

11.9

95.2

Intercompany interest

13.3

(13.3)

—

EBITDA

129.8

267.0

396.8

Non-cash stock-based compensation

12.9

3.0

15.9

Acquisition related costs

0.6

—

0.6

Securitization interest

—

(112.7)

(112.7)

Gain on sale of business

(31.6)

—

(31.6)

Severance

10.5

1.1

11.6

Foreign currency (gains)/losses

5.8

—

5.8

(Gain)/loss on investments

(0.4)

—

(0.4)

Professional fees related to business improvement efforts

1.2

0.3

1.5

Impact for newly enacted Canadian DST related to prior years

5.4

—

5.4

Other

0.3

0.2

0.5

  Total addbacks/(deductions)

4.7

(108.1)

(103.4)

Adjusted EBITDA

$          134.5

$          158.9

$          293.4

The following table reconciles operating adjusted net income and operating adjusted net income per diluted share to net income (loss) from continuing operations for the periods presented:

Three Months Ended

December 31,

Year Ended

December 31,

(In millions, except per share amounts), (Unaudited)

2024

2023

2024

2023

Net income (loss) from continuing operations

$      52.3

$      13.6

$     109.9

$   (154.8)

Acquired amortization expense

8.3

9.5

35.7

37.8

Impact for newly enacted Canadian DST related to prior years

(4.6)

—

5.4

—

Gain on sale of business

(31.6)

—

(31.6)

—

Loss on extinguishment of debt

—

—

—

1.1

Contingent consideration adjustment

—

—

—

1.3

Goodwill and other intangibles impairment

—

—

—

250.8

Income taxes (1)

6.1

(0.1)

3.3

(32.5)

Operating adjusted net income from continuing operations

$      30.5

$      23.0

$     122.7

$     103.7

Operating adjusted net income from discontinued operations

$          —

$        0.7

$          —

$        0.7

Operating adjusted net income

$      30.5

$      23.7

$     122.7

$     104.4

Operating adjusted net income from continuing operations per
share – diluted (2)

$      0.21

$      0.16

$      0.85

$      0.72

Operating adjusted net income from discontinued operations per
share – diluted

—

—

—

—

Operating adjusted net income per share – diluted

$      0.21

$      0.16

$      0.85

$      0.72

Weighted average diluted shares – including assumed conversion
of preferred shares

144.1

144.7

145.0

144.8

(1)

For the three months and years ended December 31, 2024 and 2023, each tax deductible item was booked to the applicable statutory rate. The deferred tax benefits of $52.5 million and $6.5 million associated with the goodwill and tradename impairments in 2023, respectively, resulted in the U.S. being in a net deferred tax asset position. Due to the three-year cumulative loss related to U.S. operations, we currently have a $35.8 million valuation allowance against the U.S. net deferred tax asset.

(2)

The Series A Preferred Stock dividends and undistributed earnings allocated to participating securities have not been included in the determination of operating adjusted net income for purposes of calculating operating adjusted net income per diluted share.

The following table reconciles EBITDA and Adjusted EBITDA to income from continuing operations for the 2025 guidance presented:

2025 Guidance

(In millions), (Unaudited)

Low

High

Income from continuing operations

$              100

$              114

Add back:

Income taxes

47

53

Finance interest expense

103

103

Interest expense, net of interest income

12

12

Depreciation and amortization

95

95

EBITDA

357

377

  Total addbacks/(deductions), net

(67)

(67)

Adjusted EBITDA

$              290

$              310

The following table reconciles operating adjusted net income from continuing operations and operating adjusted net income from continuing operations per diluted share to income from continuing operations for the 2025 guidance presented:

2025 Guidance

(In millions, except per share amounts), (Unaudited)

Low

High

Income from continuing operations

$              100

$              114

   Total adjustments, net

31

31

Operating adjusted net income from continuing operations

$              131

$              145

Operating adjusted net income from continuing operations per share – diluted

$             0.90

$             1.00

Weighted average diluted shares – including assumed conversion of preferred
shares

145

145

 

Analyst Inquiries:

Media Inquiries:

Itunu Orelaru

Laurie Dippold  

(317) 249-4559

(317) 468-3900

investor_relations@openlane.com 

laurie.dippold@openlane.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/openlane-inc-reports-2024-financial-results-302380654.html

SOURCE OPENLANE, Inc.

Continue Reading

Technology

STARMUS VIII — THE SEARCH FOR TRUTH

Published

on

By

From Nobel Prize Laureates and NASA Astronauts to Music Legends: STARMUS VIII Unites the World’s Greatest Minds in a Historic Celebration of Science, Music and Humanity

Tenerife & La Palma, Canary Islands, Spain | 17–22 October 2026

CANARY ISLANDS, Spain, Oct. 30, 2026 /PRNewswire/ — From the iconic sound of Sir Brian May’s legendary Red Special guitar and the extraordinary voices of Andrea Bocelli and Sarah Brightman to the groundbreaking discoveries of Nobel Prize-winning scientists, from NASA’s Artemis II astronauts preparing for humanity’s return to the Moon to historic tributes to Stephen Hawking and Jane Goodall, STARMUS VIII — The Search for Truth brought together an extraordinary constellation of scientific minds, legendary musicians, explorers and visionary thinkers for six unforgettable days in the Canary Islands.

Experience the full interactive Multichannel News Release here: https://www.multivu.com/starmus-foundation/9430551-en-starmus-viii-the-search-for-truth-festival-2026

Held across Tenerife and La Palma from 17 to 22 October 2026, the eighth edition of STARMUS transformed the islands into a global stage for scientific discovery, artistic excellence and some of the most important conversations shaping humanity’s future.

Founded by astrophysicist Dr. Garik Israelian and legendary Queen guitarist and astrophysicist Sir Brian May, STARMUS once again demonstrated its unique ability to bridge science, music and society, bringing complex scientific ideas to audiences through extraordinary encounters, performances and shared experiences.

This year’s festival marked two defining milestones: the 10th anniversary of the Stephen Hawking Medal for Science Communication and the inauguration of the Jane Goodall Earth Medal, establishing a powerful connection between humanity’s ambition to explore the universe and its responsibility to protect the planet we call home.

Media Contacts:

US: Dan DuPont, dupont0708@gmail.com, +1 202 380 7558

UK/EU: Nicole Ettinger, nicole@ettingerpr.com, +44 7515 394107

Spain: Carlos Esteban, cesteban@llys.global, +34 699 55 2854

 

 

 

 

 

 

 

 

 

 

 

 

 

 

View original content:https://www.prnewswire.com/news-releases/starmus-viii–the-search-for-truth-302924867.html

SOURCE Starmus Foundation

Continue Reading

Technology

Membrane Chromatography Market worth $0.63 billion by 2031 – Exclusive Report by MarketsandMarkets™

Published

on

By

DELRAY BEACH, Fla., Oct. 30, 2026 /PRNewswire/ — According to MarketsandMarkets™, the Membrane Chromatography Market is projected to reach USD 0.63 billion by 2031 from USD 0.37 billion in 2026, at a CAGR of 11.3% during the forecast period.

Browse 417 market data Tables and 51 Figures spread through 343 Pages and in-depth TOC on ‘Membrane Chromatography Market – Global Forecast to 2031’

Membrane Chromatography Market Size & Forecast:

Market Size Available for Years: 2026–20312026 Market Size: USD 0.37 billion2031 Projected Market Size: USD 0.63 billionCAGR (2026–2031): 11.3%

Membrane Chromatography Market Trends & Insights:

By region, North America accounted for the largest share of ~37.4% of the market in 2025.By product, the capsules, cassettes, and cartridges segment is projected to register the highest CAGR of 12.0% in the membrane chromatography market during the forecast period.By technique, the ion exchange membrane chromatography segment accounted for the largest share of 58.1% of the membrane chromatography market in 2025.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151487196

The membrane chromatography market is expected to grow steadily as pharmaceutical and biotechnology companies increase investments in biologics, biosimilars, vaccines, cell & gene therapies, and other advanced therapeutic modalities. Growing production of monoclonal antibodies, recombinant proteins, viral vectors, plasmid DNA, and mRNA is increasing demand for membrane chromatography products, including capsules, cassettes & cartridges, membrane discs & sheets, syringe filters, filter plates, spin columns, and other consumables & accessories. Rising adoption of single-use downstream processing, flow-through purification, affinity capture, and high-throughput polishing is improving process flexibility, throughput, and manufacturing efficiency. Advances in membrane materials, surface functionalization, and high-capacity affinity membranes are further enhancing selectivity, binding capacity, and purification performance. These factors are supporting adoption across pharmaceutical & biopharmaceutical companies, CROs & CDMOs, and academic & research institutes.

The market is increasingly shifting toward high-throughput, single-use, and application-specific membrane chromatography solutions that can support complex biologics and advanced therapeutic modalities. Although conventional resin-based chromatography remains widely adopted, demand is increasing for advanced membrane formats, improved ligand chemistries, higher binding capacities, and intensified flow-through and bind-elute purification approaches that can reduce processing time and improve downstream productivity. Suppliers are expanding product portfolios and developing specialized membrane chemistries to support monoclonal antibodies, viral vectors, plasmid DNA, mRNA, and other biomolecules with challenging purification requirements. At the same time, manufacturers are addressing challenges related to membrane fouling, scalability, selectivity, pressure handling, and process consistency through advanced membrane materials and optimized purification workflows. The growing outsourcing of bioprocess development and manufacturing further supports specialized membrane chromatography providers that can deliver scalable, high-throughput purification solutions with shorter turnaround times and consistent performance.

The flow-through membrane chromatography segment is expected to register the highest growth rate in the membrane chromatography market during the forecast period.

The membrane chromatography market is segmented by operation mode into flow-through membrane chromatography and bind-elute membrane chromatography. During the forecast period, flow-through membrane chromatography is projected to grow faster, supported by rising demand for high-throughput impurity removal, polishing, and process intensification in biopharmaceutical manufacturing. Flow-through processing enables rapid processing, lower pressure drops, reduced buffer consumption, and easier integration with single-use and continuous downstream workflows. However, bind-elute membrane chromatography remains an important operating mode because it supports selective capture and purification of target biomolecules across biologics and advanced therapy manufacturing applications.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=151487196

North America accounted for the largest regional share of the global membrane chromatography market in 2025.

The membrane chromatography market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2025, North America accounted for the largest share of the global market, driven by a well-established pharmaceutical and biotechnology industry, strong biopharmaceutical R&D activity, significant biologics manufacturing capacity, and widespread adoption of advanced downstream purification technologies. The region also benefits from major membrane chromatography product providers, pharmaceutical & biopharmaceutical companies, CROs & CDMOs, and research institutions. Continued development and commercialization of monoclonal antibodies, vaccines, viral vectors, and other advanced therapeutics, along with increasing adoption of single-use and high-throughput purification solutions, further support the region’s leading market position.

Key Players

Leading players in the Membrane Chromatography companies include Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Donaldson Company, Inc. (US), GVS S.p.A. (Italy), i3 Membrane GmbH (Germany), Restek Corporation (US), Shimadzu Corporation (Japan), W. L. Gore & Associates, Inc. (US), MACHEREY-NAGEL GmbH & Co. KG (Germany), and MICROSOLV (US), among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=151487196

Investment & Funding Context

The membrane chromatography market is seeing increased investment as companies and research organizations focus on developing high-capacity membranes, scaling up manufacturing, advancing continuous downstream processing, and commercializing single-use purification technologies.

In June 2026, MembraneWorks, Inc. received USD 350,000 through the North Carolina Biotechnology Center’s Small Business Research Loan program to develop high-capacity nonwoven membrane chromatography devices for biopharmaceutical purification. The funding supports further development and commercialization of membrane-based downstream purification technologies.

In June 2025, a North Carolina State University research team received funding under the Gates Foundation-supported Grand Challenges initiative to develop a low-cost, all-membrane chromatography process to purify the antimalarial monoclonal antibody MAM01. The project focuses on single-use membranes, membrane-coupled ligands, scalable device configurations, integration into single-use cassettes, and development of an affordable, scalable biomanufacturing platform. These developments indicate continued funding toward membrane chromatography commercialization, high-capacity membrane devices, single-use purification, process intensification, and scalable biologics manufacturing.

Revenue Shift Context

The membrane chromatography market is gradually shifting from conventional resin-based chromatography and standalone filtration toward a broader mix of single-use membrane adsorbers, high-capacity affinity membranes, flow-through purification solutions, and application-specific consumables. Traditional products such as capsules, cassettes & cartridges, syringe filters, filter plates, spin columns, and membrane discs & sheets remain important revenue pools; however, customers increasingly seek integrated downstream solutions supporting monoclonal antibodies, viral vectors, plasmid DNA, mRNA, and other advanced therapeutic modalities.

Rising demand for single-use and high-throughput purification is further increasing consumption of specialized membrane formats and functionalized chemistries. At the same time, growing outsourcing by pharmaceutical & biopharmaceutical companies to CROs & CDMOs is expanding revenue opportunities for scalable purification platforms and related consumables. Over the forecast period, revenue growth is therefore expected to increasingly favor recurring membrane consumables, affinity membrane chromatography, advanced membrane materials, and integrated flow-through downstream processing workflows.

Mergers & Acquisitions

Mergers & acquisitions in the membrane chromatography market are increasingly focused on expanding downstream purification capabilities, strengthening membrane and filtration portfolios, and improving access to biopharmaceutical manufacturing customers. Buyers are prioritizing technologies that complement single-use processing, membrane-based separations, and integrated upstream-to-downstream workflows.

MEMBRANE CHROMATOGRAPHY MARKET: MERGERS & ACQUISITIONS, JANUARY 2025–SEPTEMBER 2026

Month & Year

Deal Type

Company
1

Company
2

Description

September 2025

Acquisition

Thermo Fisher Scientific Inc. (US)

Solventum Corporation – Purification & Filtration Business (US)

Thermo Fisher Scientific completed the acquisition of Solventum’s Purification & Filtration business for approximately USD 4.0 billion. The acquired business includes bioprocessing filtration and membrane technologies supporting upstream and downstream biopharmaceutical manufacturing. The portfolio includes Polisher ST Membrane Adsorber, a single-use anion exchange membrane chromatography solution for flow-through polishing and removal of host cell proteins, DNA, viruses, and other impurities. The acquisition strengthens Thermo Fisher’s membrane-based purification and broader downstream bioprocessing capabilities.

Company Revenue Share Details

The top four players collectively account for approximately 73–77% of the global membrane chromatography market, indicating a consolidated landscape. The market comprises a mix of diversified life science companies and specialized membrane chromatography product manufacturers. Leading players include Danaher Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), i3 Membrane GmbH (Germany), Agilent Technologies, Inc. (US), Donaldson Company, Inc. (US), GVS S.p.A. (Italy), Restek Corporation (US), Shimadzu Corporation (Japan), W. L. Gore & Associates, Inc. (US), MACHEREY-NAGEL GmbH & Co. KG (Germany), MICROSOLV (US), among others. Their portfolio spans membrane adsorbers, capsules, cassettes & cartridges, syringe filters, filter plates, spin columns, membrane discs & sheets, and other consumables, along with ion exchange, affinity, and hydrophobic interaction membrane chromatography solutions. The coexistence of large, diversified companies and specialized membrane technology providers creates significant scope for continued competition and consolidation, particularly as companies expand single-use purification portfolios, high-capacity affinity membrane technologies, advanced membrane materials, and geographic reach.

Browse Adjacent Market: Biotechnology Market Research Reports &Consulting

See More Latest Biotechnology Reports:

Life Science Instrumentation Market by Technology (Spectroscopy, Chromatography, NGS, PCR, Microscopy, Centrifuge, Liquid Handling), Application (Diagnostic, Research), End User (Pharma-Biopharma, Food, Hospital, Academia, CRO) – Global Forecast to 2031

Chromatography Columns Market by Column Type (Ion Exchange, Size Exclusion, Reverse and Normal Phases, HPLC, Affinity, Chiral), Capacity (1-100 ml, 100-1000 ml, >1 liter), End User (Pharma & Biotech, CRO, CDMO) – Global Forecast to 2031

About MarketsandMarkets™  

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/membrane-chromatography-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/membrane-chromatography.asp

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/membrane-chromatography-market-worth-0-63-billion-by-2031—exclusive-report-by-marketsandmarkets-302924841.html

Continue Reading

Technology

In HelloNation, Assisted Living Experts Rusty and Kelly Ackerman Explain Why Amenities Matter More Than Families Expect

Published

on

By

The article examines how amenities shape daily routines, independence, and social connection in senior living communities.

TRAVERSE CITY, Mich., Oct. 30, 2026 /PRNewswire/ — Why do senior living amenities have a greater impact on daily life than many families initially expect? HelloNation has released an article that explains how these features influence comfort, independence, and social connection in meaningful ways.

The article features insights from Assisted Living Experts Rusty and Kelly Ackerman of French Manor Assisted Living in Traverse City, Michigan, and highlights how senior living amenities play a central role in shaping everyday experiences within a community.

The HelloNation article explains that while families often focus on apartments and care services, senior living amenities are deeply connected to how residents spend their time. These amenities are not simply added features but part of the daily routine that supports both independence and engagement.

Dining options are one of the most impactful elements discussed. The article notes that meals are a daily experience that influence routine, health, and social connection. Asking about variety and flexibility helps families understand how dining options support both independence and comfort over time.

The article also explains that flexible dining options allow residents to make choices about when and what they eat. This ability to choose supports independence and reinforces a sense of control, which is especially important during transitions into a new living environment.

Activity spaces are another essential component of senior living amenities. The article describes how these spaces support hobbies, group events, and informal gatherings. Well-used activity spaces encourage residents to remain engaged and provide natural opportunities for social connection throughout the day.

In addition, activity spaces help foster spontaneous interaction. Residents may gather for conversation or shared interests, which strengthens community bonds. The article emphasizes that accessible and active spaces contribute directly to both engagement and independence.

Outdoor areas also play a significant role in daily life. The article explains that access to outdoor areas allows residents to enjoy fresh air, walk safely, and experience a change of environment. These outdoor areas help create a balanced routine and support emotional well-being.

The article further notes that time spent outdoors can improve mood and reduce stress. When outdoor areas are designed with safety and accessibility in mind, they support both independence and overall comfort.

Wellness programs are another key aspect of senior living amenities. The article describes how these programs provide structure through fitness and health-focused activities. Consistent wellness programs help residents maintain strength, confidence, and long-term well-being.

Wellness programs also encourage social connection by bringing residents together in shared activities. Participation in these programs helps build relationships while supporting physical health, reinforcing a sense of purpose within the community.

The article highlights that social connection is often shaped by how effectively senior living amenities are used. Dining options, activity spaces, outdoor areas, and wellness programs all create opportunities for interaction that help residents feel connected rather than isolated.

Senior living amenities also support independence in practical ways. Easy access to these features allows residents to make choices throughout the day, reinforcing confidence and autonomy over time.

Overall, the HelloNation article emphasizes that senior living amenities play a direct role in shaping comfort, independence, and social connection. Families are encouraged to look beyond appearance and ask how these amenities function on a daily basis to better understand the full living experience.

For families evaluating options, the article provides a clear perspective on how senior living amenities contribute to quality of life in ways that may not be immediately visible during a tour.

Why Amenities Matter More Than Families Expect features insights from Rusty and Kelly Ackerman, Assisted Living Experts of Traverse City, Michigan, in HelloNation.

About HelloNation
HelloNation is America’s Good News Network, a premier media platform built on the idea that good news travels faster when real people tell real stories. Through its community-focused publications and innovative “edvertising” approach, HelloNation delivers content that informs, inspires, and spotlights the leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-hellonation-assisted-living-experts-rusty-and-kelly-ackerman-explain-why-amenities-matter-more-than-families-expect-302925027.html

SOURCE HelloNation

Continue Reading

Trending